Purification and crystallization of recombinant human TNF-like ligand TL1A

Cytokine

Volumn 40, Issue 2, 2007, Pages 115-122

  Jin, Tengchuan ^a   Kim, Sunghee ^b   Guo, Feng ^a   Howard, Andrew ^a   Zhang, Yu Zhu ^a  

^a ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

Author keywords

Angiogenesis; Cancer; DcR3; Inflammation; TNF

Indexed keywords

PROTEIN TL 1 A; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFRACTION; DIFFUSION; ESCHERICHIA COLI; GEL PERMEATION CHROMATOGRAPHY; HYDROPHOBICITY; ION EXCHANGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; HUMANS; PROTEIN STRUCTURE, QUATERNARY; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15;

ESCHERICHIA COLI;

EID: 36549032197     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2007.07.193     Document Type: Article

References (33)

1. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3 (2003) 745-756
2. Bodmer J.L., Schneider P., and Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 27 (2002) 19-26
3. Eck M.J., and Sprang S.R. The structure of tumor necrosis factor-alpha at 2.6 Å resolution. Implications for receptor binding. J Biol Chem 264 (1989) 17595-17605
4. Jones E.Y., Stuart D.I., and Walker N.P. Structure of tumour necrosis factor. Nature 338 (1989) 225-228
5. Banner D.W., D'Arcy A., Janes W., Gentz R., Schoenfeld H.J., Broger C., et al. Crystal structure of the soluble human 55 kDa TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73 (1993) 431-445
6. Karpusas M., Hsu Y.M., Wang J.H., Thompson J., Lederman S., Chess L., et al. 2 Å crystal structure of an extracellular fragment of human CD40 ligand. Structure 3 (1995) 1031-1039
7. Cha S.S., Kim M.S., Choi Y.H., Sung B.J., Shin N.K., Shin H.C., et al. 2.8 Å resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 11 (1999) 253-261
8. Lam J., Nelson C.A., Ross F.P., Teitelbaum S.L., and Fremont D.H. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 108 (2001) 971-979
9. Karpusas M., Cachero T.G., Qian F., Boriack-Sjodin A., Mullen C., Strauch K., et al. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol 315 (2002) 1145-1154
10. Hymowitz S.G., Compaan D.M., Yan M., Wallweber H.J., Dixit V.M., Starovasnik M.A., et al. The crystal structures of EDA-A1 and EDA-A2: splice variants with distinct receptor specificity. Structure 11 (2003) 1513-1520
11. Wallweber H.J., Compaan D.M., Starovasnik M.A., and Hymowitz S.G. The crystal structure of a proliferation-inducing ligand, APRIL. J Mol Biol 343 (2004) 283-290
12. Compaan D.M., and Hymowitz S.G. The crystal structure of the costimulatory OX40-OX40L complex. Structure 14 (2006) 1321-1330
13. Bossen C., Ingold K., Tardivel A., Bodmer J.L., Gaide O., Hertig S., et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 281 (2006) 13964-13971
14. Tan K.B., Harrop J., Reddy M., Young P., Terrett J., Emery J., et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204 (1997) 35-46
15. Zhai Y., Ni J., Jiang G.W., Lu J., Xing L., Lincoln C., et al. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13 (1999) 181-189
16. Migone T.S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16 (2002) 479-492
17. Wen L., Zhuang L., Luo X., and Wei P. TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J Biol Chem 278 (2003) 39251-39258
18. Papadakis K.A., Prehn J.L., Landers C., Han Q., Luo X., Cha S.C., et al. TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol 172 (2004) 7002-7007
19. Chew L.J., Pan H., Yu J., Tian S., Huang W.Q., Zhang J.Y., et al. A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 16 (2002) 742-744
20. Wang L., Pan W., Zhu F.L., Jiao B.H., Lou Y.H., Xiao Y., et al. Cloning, expression and biological activity of VEGI(151), a novel vascular endothelial cell growth inhibitor. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 32 (2000) 485-489
21. Kim S., and Zhang L. Identification of naturally secreted soluble form of TL1A, a TNF-like cytokine. J Immunol Meth 298 (2005) 1-8
22. Chen J., Zhang L., and Kim S. Quantification and detection of DcR3, a decoy receptor in TNFR family. J Immunol Meth 285 (2004) 63-70
23. Canutescu A.A., Shelenkov A.A., and Dunbrack Jr. R.L. A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci 12 (2003) 2001-2014
24. McCoy A.J., Grosse-Kunstleve R.W., Storoni L.C., and Read R.J. Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61 (2005) 458-464
25. Storoni L.C., McCoy A.J., and Read R.J. Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr 60 (2004) 432-438
26. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter C.W., and Sweet R.M. (Eds). Methods in enzymology (1997), Academic Press, New York 307-326
27. Howard A.J. Data processing in macromolecular crystallography. In: Bourne P.E., and Watenpauph K.D. (Eds). Proceedings from the macromolecular crystallography computing school, 1996 (2000), Oxford University Press, Oxford
28. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53 (1997) 240-255
29. Baeyens K.J., De Bondt H.L., Raeymaekers A., De Ranter C.J., and Fiers W. Crystallization and preliminary x-ray studies of mouse tumor necrosis factor. Acta Crystallogr D Biol Crystallogr 53 (1997) 329-330
30. Hymowitz S.G., Christinger H.W., Fuh G., Ultsch M., O'Connell M., Kelley R.F., et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 4 (1999) 563-571
31. Bodmer J.L., Meier P., Tschopp J., and Schneider P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem 275 (2000) 20632-20637
32. Hymowitz S.G., O'Connell M.P., Ultsch M.H., Hurst A., Totpal K., Ashkenazi A., et al. A unique zinc-binding site revealed by a high-resolution x-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39 (2000) 633-640
33. Cha S.S., Sung B.J., Kim Y.A., Song Y.L., Kim H.J., Kim S., et al. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem 275 (2000) 31171-31177